ScreenerHero

PVLA Palvella Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · palvellatx.com
130.59USD+2.02%Mkt Cap: 1.88B $P/E: —

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product cand…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.88B USD
Enterprise Value1.62B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-41.72M USD
Revenue/Share—
Last Price130.59 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.07
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B8.50
EPS (TTM)-4.69
EPS (Forward)-7.50
52W Range
56.5471% of range161.38
52W High161.38 USD
52W Low56.54 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-149.07%
ROA-70.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.01M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.35%
Net Debt-227.94M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio21.18
Quick Ratio21.01
Book Value/Sh15.06 USD
Cash/Share17.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:80
Split DateApr 23, 2024
Analyst Consensus
Rating—
Target (Mean)230.53 USD
Upside (mean)+76.5%
Target Range205.00 USD – 270.00 USD
205.00+76.5% to mean270.00
# Analysts15
Ownership
Shares Out.14.41M
Float10.68M
Insiders11.59%
Institutions103.83%
Short Interest
Short Ratio11.8d
Short % Float18.26%
Short % Out.16.14%
Shares Short2.33M
Short (prev mo.)2.15M
Technical
SMA 50148.60 (-12.1%)
SMA 200123.93 (+5.4%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)216.22K
Avg Vol (10d)232.74K
Technical Indicators
RSI (14)35.4
MACD-5.0786
MACD Signal-3.0519
MACD Hist.-2.0267
BB Upper162.97 USD
BB Middle143.97 USD
BB Lower124.97 USD
BB Width26.39%
ATR (14)7.034 USD
Vol Ratio (20d)0.63x